Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

292 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Detection of SARS-CoV-2 in Saliva and Nasopharyngeal Swabs According to Viral Variants.
Salmona M, Chaix ML, Feghoul L, Mahjoub N, Maylin S, Schnepf N, Jacquier H, Walle EM, Helary M, Mellon G, Osinski N, Zebiche W, Achili Y, Amarsy R, Mahé V, Le Goff J, Delaugerre C. Salmona M, et al. Among authors: delaugerre c. Microbiol Spectr. 2022 Dec 21;10(6):e0213322. doi: 10.1128/spectrum.02133-22. Epub 2022 Nov 8. Microbiol Spectr. 2022. PMID: 36346252 Free PMC article.
No evidence of rapid antiviral clearance or clinical benefit with the combination of hydroxychloroquine and azithromycin in patients with severe COVID-19 infection.
Molina JM, Delaugerre C, Le Goff J, Mela-Lima B, Ponscarme D, Goldwirt L, de Castro N. Molina JM, et al. Among authors: delaugerre c. Med Mal Infect. 2020 Jun;50(4):384. doi: 10.1016/j.medmal.2020.03.006. Epub 2020 Mar 30. Med Mal Infect. 2020. PMID: 32240719 Free PMC article. Clinical Trial. No abstract available.
Frequency of relapse and persistent cutaneous symptoms after a first episode of chilblain-like lesion during the COVID-19 pandemic.
Moghadam P, Frumholtz L, Jaume L, De Masson A, Jachiet M, Begon E, Sulimovic L, Petit A, Bachelez H, Bagot M, Bouaziz JD, Cassius C; Saint-Louis CORE (COvid REsearch). Moghadam P, et al. J Eur Acad Dermatol Venereol. 2021 Sep;35(9):e566-e568. doi: 10.1111/jdv.17393. Epub 2021 Jun 19. J Eur Acad Dermatol Venereol. 2021. PMID: 34036642 Free PMC article. No abstract available.
Safety and efficacy of switching to elvitegravir, cobicistat, emtricitabine, tenofovir disoproxil fumarate in treatment-experienced people with HIV: a multicenter cohort study.
De Castro N, Brun A, Sellier P, Hamet G, Mechaï F, Garrait V, Chabrol A, Bouldouyre MA, Froguel E, Troisvallets D, Caraux-Paz P, Delaugerre C, Rozenbaum W, Molina JM. De Castro N, et al. Among authors: delaugerre c. AIDS Res Ther. 2023 Jan 3;20(1):1. doi: 10.1186/s12981-022-00499-4. AIDS Res Ther. 2023. PMID: 36597160 Free PMC article.
Second clinical episode of hMPX virus in a man having sex with men.
Zeggagh J, Ferraris O, Salmona M, Tarantola A, Molina JM, Delaugerre C. Zeggagh J, et al. Among authors: delaugerre c. Lancet. 2023 May 13;401(10388):1610. doi: 10.1016/S0140-6736(23)00509-3. Epub 2023 Mar 24. Lancet. 2023. PMID: 36972717 No abstract available.
Virologic response to antiretroviral therapy in people with HIV and tuberculosis in high tuberculosis burden countries.
De Castro N, Chazallon C, Brites C, Messou E, Khosa C, Laureillard D, Chau GD, Pilotto JH, Eholié S, Delaugerre C, Molina JM, Wittkop L, Grinsztejn B, Marcy O. De Castro N, et al. Among authors: delaugerre c. AIDS. 2023 Oct 1;37(12):1837-1842. doi: 10.1097/QAD.0000000000003521. Epub 2023 Feb 16. AIDS. 2023. PMID: 36928120 Clinical Trial.
Comparison of resistance mutation patterns in historical plasma HIV RNA genotypes with those in current proviral HIV DNA genotypes among extensively treated patients with suppressed replication.
Delaugerre C, Braun J, Charreau I, Delarue S, Nere ML, de Castro N, May T, Marchou B, Simon F, Molina JM, Aboulker JP; ANRS 138-EASIER study group. Delaugerre C, et al. HIV Med. 2012 Oct;13(9):517-25. doi: 10.1111/j.1468-1293.2012.01002.x. Epub 2012 Mar 14. HIV Med. 2012. PMID: 22416781 Free article. Clinical Trial.
Archived HIV-1 DNA resistance mutations to rilpivirine and etravirine in successfully treated HIV-1-infected individuals pre-exposed to efavirenz or nevirapine.
Gallien S, Charreau I, Nere ML, Mahjoub N, Simon F, de Castro N, Aboulker JP, Molina JM, Delaugerre C. Gallien S, et al. Among authors: delaugerre c. J Antimicrob Chemother. 2015 Feb;70(2):562-5. doi: 10.1093/jac/dku395. Epub 2014 Oct 25. J Antimicrob Chemother. 2015. PMID: 25344807 Clinical Trial.
292 results